Howe JA - Search Results

1

Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial.

Ogert RA, Howe JA, Vierling JM, Kwo PY, Lawitz EJ, McCone J, Schiff ER, Pound D, Davis MN, Gordon SC, Ravendhran N, Rossaro L, Jacobson IM, Ralston R, Chaudhri E, Qiu P, Pedicone LD, Brass CA, Albrecht JK, Barnard RJ, Hazuda DJ, Howe AY. Ogert RA, et al. Among authors: howe ay, howe ja. Antivir Ther. 2013;18(3):387-97. doi: 10.3851/IMP2549. Epub 2013 Feb 13. Antivir Ther. 2013. PMID: 23406826 Clinical Trial.

2

Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C.

Howe AY, Long J, Nickle D, Barnard R, Thompson S, Howe J, Alves K, Wahl J. Howe AY, et al. Antiviral Res. 2015 Jan;113:71-8. doi: 10.1016/j.antiviral.2014.10.010. Epub 2014 Oct 24. Antiviral Res. 2015. PMID: 25446895 Clinical Trial.

3

Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies.

Barnard RJ, Howe JA, Ogert RA, Zeuzem S, Poordad F, Gordon SC, Ralston R, Tong X, Sniukiene V, Strizki J, Ryan D, Long J, Qiu P, Brass CA, Albrecht J, Burroughs M, Vuocolo S, Hazuda DJ. Barnard RJ, et al. Among authors: howe ja. Virology. 2013 Sep;444(1-2):329-36. doi: 10.1016/j.virol.2013.06.029. Epub 2013 Jul 19. Virology. 2013. PMID: 23876458 Free article.

4

Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.

Flamm SL, Lawitz E, Jacobson I, Bourlière M, Hezode C, Vierling JM, Bacon BR, Niederau C, Sherman M, Goteti V, Sings HL, Barnard RO, Howe JA, Pedicone LD, Burroughs MH, Brass CA, Albrecht JK, Poordad F. Flamm SL, et al. Among authors: howe ja. Clin Gastroenterol Hepatol. 2013 Jan;11(1):81-87.e4; quiz e5. doi: 10.1016/j.cgh.2012.10.006. Epub 2012 Oct 10. Clin Gastroenterol Hepatol. 2013. PMID: 23064222 Clinical Trial.

5

Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3.

Silva MO, Treitel M, Graham DJ, Curry S, Frontera MJ, McMonagle P, Gupta S, Hughes E, Chase R, Lahser F, Barnard RJ, Howe AY, Howe JA. Silva MO, et al. Among authors: howe ay, howe ja. J Hepatol. 2013 Jul;59(1):31-7. doi: 10.1016/j.jhep.2013.02.018. Epub 2013 Feb 27. J Hepatol. 2013. PMID: 23454058 Clinical Trial.

6

Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5.

Ogert RA, Hou Y, Ba L, Wojcik L, Qiu P, Murgolo N, Duca J, Dunkle LM, Ralston R, Howe JA. Ogert RA, et al. Among authors: howe ja. Virology. 2010 Apr 25;400(1):145-55. doi: 10.1016/j.virol.2010.01.037. Epub 2010 Feb 21. Virology. 2010. PMID: 20172579 Free article.

7

Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/Ribavirin.

Howe JA, Long J, Black S, Chase R, McMonagle P, Curry S, Thompson S, DiNubile MJ, Howe AY. Howe JA, et al. Among authors: howe ay. Open Forum Infect Dis. 2014 Sep 16;1(2):ofu078. doi: 10.1093/ofid/ofu078. eCollection 2014 Sep. Open Forum Infect Dis. 2014. PMID: 25734146 Free PMC article.

8

Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc.

Ogert RA, Ba L, Hou Y, Buontempo C, Qiu P, Duca J, Murgolo N, Buontempo P, Ralston R, Howe JA. Ogert RA, et al. Among authors: howe ja. J Virol. 2009 Dec;83(23):12151-63. doi: 10.1128/JVI.01351-09. Epub 2009 Sep 23. J Virol. 2009. PMID: 19776131 Free PMC article.

9

Quantifying the relationship between HIV-1 susceptibility to CCR5 antagonists and virus affinity for antagonist-occupied co-receptor.

Buontempo PJ, Wojcik L, Buontempo CA, Ogert RA, Strizki JM, Howe JA, Ralston R. Buontempo PJ, et al. Among authors: howe ja. Virology. 2009 Dec 20;395(2):268-79. doi: 10.1016/j.virol.2009.09.029. Epub 2009 Oct 20. Virology. 2009. PMID: 19846188 Free article.

10

Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120.

Ogert RA, Wojcik L, Buontempo C, Ba L, Buontempo P, Ralston R, Strizki J, Howe JA. Ogert RA, et al. Among authors: howe ja. Virology. 2008 Apr 10;373(2):387-99. doi: 10.1016/j.virol.2007.12.009. Epub 2008 Jan 10. Virology. 2008. PMID: 18190945 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

96 results

Search Page

Filters